Skip to content

Adis in touch

A blog from Adis, a leading global provider of drug information.

Search for:

Recent Posts

Baricitinib (Olumiant™): Now also available in the USA
Ibalizumab (Trogarzo™): First Global Approval – Blocking HIV entry to CD4 cells may open options for combination therapy in patients with multi-resistant HIV infection
Bictegravir (Biktarvy®): Positive CHMP Opinion in the EU
Burosumab (Crysvita®): First Global Approval – Infrastructure repair for patients with X-linked hypophosphataemia
Revolution, innovation, and collaboration: report from the World Drug Safety Congress

Recent Comments

	Revolution, innovati… on Using state-of-the-art technol…
	Durvalumab (IMFENZI®… on Durvalumab (Imfinzi™): First G…
	Inotuzumab ozogamici… on Inotuzumab Ozogamicin (Bespons…
	Ocrelizumab (Ocrevus… on Ocrelizumab (Ocrevus™): First…
	Plecanatide (Trulanc… on Plecanatide (Trulance™): First…

Archives

Categories

Adis (69)
Adis Journals (78)
Adis Pharmacovigilance (20)
AdisInsight (81)
Uncategorized (2)

July 5, 2017 2551 × 1914

2.Co-editorsofnewacademicbook

Leave a Reply Cancel reply

Powered by WordPress.com.